Bolt Biotherapeutics, Inc. (BOLT) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on May 12, 2026, by Bolt Biotherapeutics, Inc., a Delaware corporation. The filing announces the Company's financial results for the first quarter ended March 31, 2026, and provides a business update. The Company is an emerging growth company listed on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the provided text.
Material Changes
The filing text does not disclose specific material changes versus the prior comparable period. Investors must refer to the referenced press release (Exhibit 99.1) for comparative financial data and operational updates.
Guidance, Outlook, and Risks
The filing references a business update and financial results announcement but does not contain specific guidance, outlook figures, management commentary, or risk factors within the text provided. The document explicitly states that the information is furnished and not "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 12, 2026) for specific Q1 2026 financial figures.
- Verify the Company's cash runway and burn rate as detailed in the full press release.
- Confirm any updates to clinical trial timelines or regulatory milestones mentioned in the business update.
- Check for any new debt instruments or equity financing activities disclosed in the full report.